<p>根据公司在最近向证券交易委员会的披露，Evergreen Capital Management LLC 在第四季度减少了对礼来公司的持股，下降幅度为 8.6%。该基金在季度内出售了 968 股后，持有该公司 10,288 股股票。截至其最近向证券交易委员会的备案，Evergreen Capital Management LLC 在礼来公司的持股价值为 7,942,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>目前哪个医疗保健股票是最佳购买？</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也对该公司的持股进行了调整。Highline Wealth Partners LLC 在第四季度将其在礼来公司的持股增加了 80.0%。Highline Wealth Partners LLC 现在拥有 45 股该公司的股票，价值 35,000 美元，此前在上个季度又购买了 20 股。FPC Investment Advisory Inc.在第四季度将其在礼来公司的持股增加了 358.3%。FPC Investment Advisory Inc.现在拥有 55 股该公司的股票，价值 45,000 美元，此前又购买了 43 股。Prudent Man Investment Management Inc.在第四季度购买了礼来公司的新头寸，价值约 48,000 美元。Compass Financial Services Inc 在第四季度购买了礼来公司的新头寸，价值约 50,000 美元。最后，Fiduciary Advisors Inc.在第四季度购买了礼来公司的新股份，价值约 58,000 美元。机构投资者持有该公司 82.53% 的股票。</p>
<h2>分析师评级上调与下调</h2>
<p>LLY 成为多份研究分析师报告的主题。高盛集团在 4 月 8 日的研究报告中将礼来公司的股票评级从 “中性” 上调至 “买入”，并将该公司的目标价从 892.00 美元下调至 888.00 美元。Leerink Partners 在 1 月 17 日的研究报告中为礼来公司设定了 950.00 美元的目标价。摩根士丹利在 4 月 9 日的报告中将礼来公司的目标价从 1,146.00 美元下调至 1,124.00 美元，并为该公司设定了 “增持” 评级。富国银行在 3 月 5 日的报告中将礼来公司的目标价从 970.00 美元上调至 1,100.00 美元，并给予该公司 “增持” 评级。最后，StockNews.com 在 2 月 7 日的研究报告中将礼来公司的股票评级从 “持有” 上调至 “买入”。两位股票研究分析师对该股票给予了持有评级，十八位分析师对该公司给予了买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 1,012.00 美元。</p>
<ul>
<li>价格目标显示这三只股票接近 1 万亿美元的标志</li>
</ul>
<p><strong>阅读我们关于礼来公司的最新报告</strong></p>
<h2>礼来公司股票表现</h2>
<p>NYSE LLY 的股票在周三开盘价为 756.55 美元。该公司的市值为 7173.4 亿美元，市盈率为 64.61，市盈增长比率为 1.40，贝塔值为 0.51。礼来公司的 52 周低点为 677.09 美元，52 周高点为 972.53 美元。该公司的债务与股本比率为 2.00，速动比率为 0.97，流动比率为 1.15。该公司的 50 日移动平均线为 832.96 美元，200 日移动平均线为 821.54 美元。</p>
<ul>
<li>AbbVie 股票通过进入减肥市场提升投资组合</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）在 2 月 6 日星期四发布了其财报。该公司报告季度每股收益为 5.32 美元，低于分析师一致预期的 5.45 美元，差额为 0.13 美元。礼来公司的股本回报率为 85.24%，净利润率为 23.51%。整体来看，分析师预计礼来公司在当前财政年度将发布 23.48 美元的每股收益。</p>
<h2>内部人员买卖</h2>
<p>在相关消息中，首席会计官 Donald A. Zakrowski 于 3 月 13 日星期四出售了该公司 1,000 股股票。该股票以 818.24 美元的平均价格出售，总价值为 818,240.00 美元。出售完成后，首席会计官现在直接持有该公司 5,840 股股票，价值 4,778,521.60 美元。此次交易代表其持股减少了 14.62%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。公司内部人士目前持有 0.13% 的股票。</p>
<h2>礼来公司公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票比礼来公司更好</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>小心 BigBear.ai：内部人士正在出售——你应该怎么办？</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>CrowdStrike 股票在网络威胁环境扩展时是买入</li>
<li>每月股息股票的利弊</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Evergreen Capital Management LLC 在第四季度减少了对礼来公司的持股，减持幅度为 8.6%，出售了 968 股，剩余持股为 10,288 股，价值约为 794 万美元。其他机构投资者也调整了他们的持仓，其中 Highline Wealth Partners LLC 和 FPC Investment Advisory Inc. 的增持尤为显著。分析师们已上调了礼来股票的评级，普遍评级为 “适度买入”，目标价为 1,012.00 美元。该股票开盘价为 756.55 美元，市值为 7173.4 亿美元，市盈率为 64.61</p>

<p>Evergreen Capital Management LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 8.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 10,288 shares of the company's stock after selling 968 shares during the quarter. Evergreen Capital Management LLC's holdings in Eli Lilly and Company were worth $7,942,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会的披露，Evergreen Capital Management LLC 在第四季度减少了对礼来公司的持股，下降幅度为 8.6%。该基金在季度内出售了 968 股后，持有该公司 10,288 股股票。截至其最近向证券交易委员会的备案，Evergreen Capital Management LLC 在礼来公司的持股价值为 7,942,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪个医疗保健股票是最佳购买？</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the company. Highline Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after purchasing an additional 20 shares in the last quarter. FPC Investment Advisory Inc. increased its holdings in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth about $48,000. Compass Financial Services Inc bought a new position in Eli Lilly and Company during the 4th quarter valued at about $50,000. Finally, Fiduciary Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $58,000. Institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也对该公司的持股进行了调整。Highline Wealth Partners LLC 在第四季度将其在礼来公司的持股增加了 80.0%。Highline Wealth Partners LLC 现在拥有 45 股该公司的股票，价值 35,000 美元，此前在上个季度又购买了 20 股。FPC Investment Advisory Inc.在第四季度将其在礼来公司的持股增加了 358.3%。FPC Investment Advisory Inc.现在拥有 55 股该公司的股票，价值 45,000 美元，此前又购买了 43 股。Prudent Man Investment Management Inc.在第四季度购买了礼来公司的新头寸，价值约 48,000 美元。Compass Financial Services Inc 在第四季度购买了礼来公司的新头寸，价值约 50,000 美元。最后，Fiduciary Advisors Inc.在第四季度购买了礼来公司的新股份，价值约 58,000 美元。机构投资者持有该公司 82.53% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>LLY has been the topic of a number of research analyst reports. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lowered their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Morgan Stanley cut their price objective on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, April 9th. Wells Fargo &amp; Company increased their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, March 5th. Finally, StockNews.com raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $1,012.00.</p>
<div class="lb-trans"><p>LLY 成为多份研究分析师报告的主题。高盛集团在 4 月 8 日的研究报告中将礼来公司的股票评级从 “中性” 上调至 “买入”，并将该公司的目标价从 892.00 美元下调至 888.00 美元。Leerink Partners 在 1 月 17 日的研究报告中为礼来公司设定了 950.00 美元的目标价。摩根士丹利在 4 月 9 日的报告中将礼来公司的目标价从 1,146.00 美元下调至 1,124.00 美元，并为该公司设定了 “增持” 评级。富国银行在 3 月 5 日的报告中将礼来公司的目标价从 970.00 美元上调至 1,100.00 美元，并给予该公司 “增持” 评级。最后，StockNews.com 在 2 月 7 日的研究报告中将礼来公司的股票评级从 “持有” 上调至 “买入”。两位股票研究分析师对该股票给予了持有评级，十八位分析师对该公司给予了买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 1,012.00 美元。</p>
</div><ul>
<li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li>
</ul>
<div class="lb-trans"><ul>
<li>价格目标显示这三只股票接近 1 万亿美元的标志</li>
</ul>
</div><p><strong>Read Our Latest Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于礼来公司的最新报告</strong></p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>礼来公司股票表现</h2>
</div><p>Shares of NYSE LLY opened at $756.55 on Wednesday. The company has a market cap of $717.34 billion, a P/E ratio of 64.61, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm's fifty day moving average is $832.96 and its two-hundred day moving average is $821.54.</p>
<div class="lb-trans"><p>NYSE LLY 的股票在周三开盘价为 756.55 美元。该公司的市值为 7173.4 亿美元，市盈率为 64.61，市盈增长比率为 1.40，贝塔值为 0.51。礼来公司的 52 周低点为 677.09 美元，52 周高点为 972.53 美元。该公司的债务与股本比率为 2.00，速动比率为 0.97，流动比率为 1.15。该公司的 50 日移动平均线为 832.96 美元，200 日移动平均线为 821.54 美元。</p>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 股票通过进入减肥市场提升投资组合</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）在 2 月 6 日星期四发布了其财报。该公司报告季度每股收益为 5.32 美元，低于分析师一致预期的 5.45 美元，差额为 0.13 美元。礼来公司的股本回报率为 85.24%，净利润率为 23.51%。整体来看，分析师预计礼来公司在当前财政年度将发布 23.48 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员买卖</h2>
</div><p>In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席会计官 Donald A. Zakrowski 于 3 月 13 日星期四出售了该公司 1,000 股股票。该股票以 818.24 美元的平均价格出售，总价值为 818,240.00 美元。出售完成后，首席会计官现在直接持有该公司 5,840 股股票，价值 4,778,521.60 美元。此次交易代表其持股减少了 14.62%。该出售在向证券交易委员会的备案中披露，相关信息可通过此链接获取。公司内部人士目前持有 0.13% 的股票。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比礼来公司更好</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>小心 BigBear.ai：内部人士正在出售——你应该怎么办？</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>CrowdStrike 股票在网络威胁环境扩展时是买入</li>
<li>每月股息股票的利弊</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Evergreen Capital Management LLC 出售了礼来公司（NYSE:LLY）的 968 股股份